1 1 Abbreviations: RIDT: rapid influenza antigen diagnostic test; NAAT: nucleic acid amplification test; qRT-PCR: quantitative reverse transcription-polymerase chain reaction. 1
Introduction
The rapid influenza antigen diagnostic test (RIDT) using immunochromatography is used widely to detect viral antigens. RIDT requires no special skills or instruments and has a short turnaround time; therefore, it is a common point-of-care test for the detection of influenza virus infections (Welch and Ginocchio, 2010) . Although its usual specificity exceeds 90%, its analytical sensitivity is variable, ranging from 10% to 80% (Chartrand et al., 2012; Uyeki et al., 2009 ). This variability may be attributable to that remained after RIDT was stored at -80°C until RNA extraction.
Viral RNA preparation
Viral RNA was extracted directly from a 140-µL viral suspension using a QIAamp Viral RNA Mini kit (QIAGEN, Hilden, Germany) and digested with Amplification Grade DNase I (Sigma Aldrich, St. Louis, MO, USA) according to the manufacturer's instructions. Subsequently, the viral RNA was diluted with four volumes of RNase-free water and used as the template for qRT-PCR. For the positive control, AMPLIRUN Influenza A H1, H3, and B RNA controls were purchased from Vircell Microbiologists (Granada, Spain).
Primer and probe design for qRT-PCR
The primers used for influenza A virus quantification were modified partially from those described previously (Centre for Health Protection, 2009; Ward et al., 2004) , and the probe was selected from the Universal Probe Library (Roche Applied Science, Mannheim, Germany). The primers and probes used for influenza A virus subtyping (Centre for Health Protection, 2009) and influenza B virus quantification were as described previously (van Elden et al., 2001; Wu et al., 2008) , with modifications.
Preparation of viral RNA standards for viral load quantification
Complementary DNA was synthesized from AMPLIRUN Influenza A H3 and B RNA controls using SuperScript III Reverse Transcriptase (Invitrogen, Carlsbad, CA, USA) and random primers (Invitrogen). PCR was performed with AmpliTaq Gold (Applied Biosystems, Foster City, CA, USA) to amplify a matrix gene of the influenza A virus and a hemagglutinin gene of the influenza B virus using primers FLUAM-1F/1R and INFB-1/2, respectively ( Table 1) . The PCR products were isolated and purified using a QIAquick PCR purification kit (QIAGEN) before cloning with a TA PCR Cloning kit (pTAC-1; Bio Dynamics Laboratory, Tokyo, Japan). Plasmids were recovered using a QIAprep Spin Miniprep kit (QIAGEN) and sequenced with a 3130 Genetic Analyzer (Applied Biosystems). The plasmid of influenza A was amplified further with PCR using primers FLUAM-1R and M13-T7_rev (5′-TTCTAATACGACTCACTATAGGGCGGATAACAATTTCACACAG-3′). The PCR product was purified with the QIAquick PCR purification kit and used as the template for in vitro transcription. The plasmid of influenza B was digested by the restriction enzyme BamHΙ (Takara Bio, Shiga, Japan) and purified using the QIAquick PCR purification kit. RNA was synthesized via in vitro transcription using a MEGAshortscript T7 kit (Ambion, Austin, TX, USA) and purified using a MEGAclear kit (Ambion). Purified RNA was separated via MultiNA capillary electrophoresis (Shimadzu, Kyoto, Japan), and a single band was confirmed.
qRT-PCR
One-step RT-PCR was performed using LightCycler 480 RNA Master Hydrolysis Probes (Roche Applied Science) in 20-µL reaction mixtures containing 5 µL diluted viral RNA, 7.3 µL LightCycler 480 RNA Master Hydrolysis Probes (2.7 × conc.), 1.3 µL Activator, 1 µL Enhancer (20 × conc.), 0.5 µM primer (each), and 0.25 µM probe (each). The primers and probes used are shown in Table 1 . RT-PCR conditions were 63°C for 3 min and 95°C for 30 s, followed by 45 cycles of 95°C for 10 s and 58°C for 30 s. Standard curves were drawn from serial dilutions of viral RNA standards. For positive RIDT samples, either the influenza A or the influenza B virus was quantified.
For negative RIDT samples, the influenza A and B viruses were quantified separately.
qRT-PCR was performed using both H1 and H3 primers for positive RIDT samples to subtype the influenza A virus biplex. For negative RIDT samples, qRT-PCR was performed separately for H1 and H3 subtyping because the biplex reaction was found to be less sensitive than the monoplex reaction.
Results

Comparison of RIDT and qRT-PCR results
RIDT showed a positive result in 34 of 255 samples, which included 31 seasonal influenza A and 3 influenza B infections ( Fig. 1 ). Pandemic influenza A 2009 (H1N1) was not detected in any sample. qRT-PCR was performed using these 34 positive RIDT samples and 77 randomly selected negative RIDT samples obtained from 101 patients.
The median age of the patients was 42 years (range, 0-92 years). All patients, except two, had fever, respiratory symptoms, or both. The median time from illness onset to specimen collection was 1 day (range, 0 to >7 days). The two patients without fever and respiratory signs lived with persons infected with influenza virus. Viral RNA was readily amplified in all of the positive RIDT samples in concordance with the type of influenza virus. For the 77 negative RIDT samples, amplification was observed clearly in 22 samples for influenza A, three for influenza B, and one for both influenza types, whereas 51 samples lacked amplification for either influenza A or B (Fig. 1) .
Limits of detection of RIDT and qRT-PCR
Viral copy number was assessed in 34 positive and 26 negative RIDT samples that were determined to be positive using qRT-PCR. The quantum of the influenza A viral load ranged from 10 7 to 10 11 copies/mL in the positive RIDT samples and 10 3 to 10 8 copies/mL in the negative RIDT samples (Fig. 2) . The quantum of the influenza B virus ranged from 10 5 to 10 9 copies/mL in the positive RIDT samples and 10 3 to 10 5 copies/mL in the negative RIDT samples (see Fig. 2 ). Accordingly, the limit of detection of RIDT was 10 7 to 10 8 copies/mL for influenza A and 10 5 copies/mL for influenza B, whereas that of qRT-PCR was 10 3 copies/mL for both influenza A and B. These outcomes indicate that low copy numbers of the viruses that result in negative RIDT results can be detected with qRT-PCR.
Influenza A virus subtyping
Influenza A subtype was determined using subtype-specific primers and probes for 31 influenza A samples detected by RIDT and 23 influenza A samples detected by qRT-PCR but not RIDT. The 31 samples detected by RIDT were amplified clearly by H3 primers. In the 23 samples detected by only qRT-PCR, eight samples were amplified by H3 primers and 15 samples were amplified by neither H3 nor H1 primers, perhaps due to the low viral copy number. Therefore, all influenza A viruses amplified by subtype-specific primers were of the H3 subtype.
Clinical outcome of patients with false-negative RIDT results
The clinical outcome of the 24 patients with positive qRT-PCR but negative RIDT results was assessed retrospectively. All of the patients except one received no antiviral agents, whereas 20 patients were prescribed antibiotics. During antibiotic therapy, a patient showed serious influenza symptoms for more than 8 days in the absence of a clear diagnosis. Another patient was admitted after antibiotic therapy with a diagnosis of pneumonia and was further treated with another antibiotic. Some of the other patients received multiple examinations to determine causes for their illness other than influenza virus, but ultimately, the results did not account for their symptoms.
Discussion
Despite inappropriate treatment in patients with positive qRT-PCR results but negative RIDT results, all patients who did not receive antivirals recovered eventually from their influenza symptoms. However, the illnesses of two patients progressed to pneumonia with hypoxia. One developed pneumonia after steroid pulse therapy for myelitis. RIDT was performed 4 days after fever onset and gave a negative result, whereas qRT-PCR detected 1.3 × 10 5 copies/mL of influenza A virus in the same specimen. Bronchoscopy and blood tests performed to obtain causal information did not result in a definitive diagnosis. This patient also presented with encephalopathy, although its relevance to the influenza virus was unclear. The other patient developed pneumonia and serious hypoxia with pulmonary oedema due to chronic renal failure. RIDT was performed once on days 1 and 2 after symptom onset, but the results for both specimens were negative, whereas qRT-PCR detected 1.24 × 10 5 copies/mL of influenza B virus in the second specimen. These results indicate that infection with even a small amount of influenza virus can have serious outcomes if patients are at risk for complications such as immunosuppressive therapy or chronic renal dysfunction.
The RIDT results were obtained using one commercial kit in this study.
However, the stability of viral RNA in the solution included with RIDT kits was evaluated with qRT-PCR using two RIDT kits: Clearline Influenza A/B and QuickNavi-Flu (Denka Seiken, Niigata, Japan). A clinical viral sample was placed in the solution provided by each kit and stored under various conditions to select a kit and determine a storage condition for the experiments. The qRT-PCR results showed that viral RNA was sufficiently amplified without remarkable degradation when samples were stored at -80°C, and no substantial differences were found between the two kits (data not shown). These results suggest that the kit used in the experiments was representative of other commercially available RIDT kits.
The present study provides evidence that influenza infection cannot be ruled out by negative RIDT results because the test has low sensitivity. Particularly when influenza activity is high, the negative predictive value of RIDT is low, and therefore the chance that a negative result is a true negative is also low (Harper et al., 2009 ). Nevertheless, antiviral treatment was not initiated for most patients who tested negative 
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